Skip to main content

Table 1 Ongoing clinical trials testing immunotherapeutic agents in BCC patients

From: Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature

Agent Phase Condition Intervention Status ID
Talimogene Laherparepvec I Non-melanoma Skin Cancer Evaluation of the mechanism of action of talimogene laherparepvec (T-VEC) in patients with locally advanced non-melanoma skin cancer Not yet recruiting NCT03458117
Basal Cell Carcinoma
Squamous Cell Carcinoma Cutaneous Lymphoma
Merkel Cell Carcinoma
ASN-002 I/II Basal Cell Carcinoma in Basal Cell Nevus Syndrome Study of ASN-002 to Treat Basal Cell Carcinomas in Individuals with Basal Cell Nevus Syndrome Not yet recruiting NCT03208296
REGN2810 II Basal Cell Carcinoma Anti-PD-1 in Patients with Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy Recruiting NCT03132636
Nivolumab + Talimogene Laherparepvec II Refractory Lymphomas Advanced or Refractory Non-melanoma Skin Cancers Talimogene Laherparepvec and Nivolumab in Treating Patients with Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625
Pembrolizumab +/− Vismodegib II Skin Basal Cell Carcinoma Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer Active, not recruiting NCT02690948
ASN-002 +/− 5-FU I/II Basal Cell Nevus Syndrome Skin Neoplasm Nodular Basal Cell Carcinoma of Skin A Study of the Efficacy and Safety of ASN-002 in Adult Patients with Low-risk Nodular Basal Cell Carcinoma Recruiting NCT02550678